3 patents currently held
31 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2030. from the record
Of the 31 now held by other companies, 15 name Boehringer Ingelheim International GmbH as their current owner, and 16 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
May 2030
Next term end
3
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2030 · High confidence
Also notable
Ends Jun 2031 · High confidence
Also notable
Ends Aug 2035 · High confidence
Compounds and Compositions for Treating Chemical Warfare Agent-Induced Injuries
US 8,318,728
Renewed at every maintenance window since the 2012 grant; no more fees are due before its term ends in 2030.
Modulators of sperm hypermotility and uses thereof
US 8,394,840
Renewed at every maintenance window since the 2013 grant; no more fees are due before its term ends in 2031.
PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES
US 9,440,973
Granted 2016 and renewed at every maintenance window due so far. Protection runs to 2035.
Formerly held, still cited
Notable
Ends Jan 2028 · High confidence
Cited by 37 later US patents, top 25% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
now held by Orvida Pharma Ltd.
Also notable
Ends Jul 2029 · High confidence
The most cited patent in this portfolio, cited by 43 later US patents, top 25% of utility patents granted in 2012 in our data. Protection runs to 2029.
now held by Eli Lilly and Company
Also notable
Ends Mar 2034 · High confidence
The largest patent family in this portfolio, 7 related applications, renewed at every maintenance window due so far. Protection runs to 2034.
now held by Boehringer Ingelheim International GmbH
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 1 term has ended since Aug 18, 2026
What they patent
The 2 largest of its 3 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Modulators of sperm hypermotility and uses thereof | 1 in force | to Jun 2031 |
| Compounds and Compositions for Treating Chemical Warfare Agent-Induced Injuries | 1 in force | to May 2030 |
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,318,728 | Compounds and Compositions for Treating Chemical Warfare Agent-Induced Injuries In force · High confidence | In force | High confidence | |
| US 8,394,840 | Modulators of sperm hypermotility and uses thereof In force · High confidence | In force | High confidence | |
| US 9,440,973 | PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES In force · High confidence | In force | High confidence |
Also on record, not counted in the 3: 31 patents in force now held by others · 19 patents ended · 29 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.